EUROPEAN UROLOGY XXX (2015) XXX–XXX

available at www.sciencedirect.com
journal homepage: www.europeanurology.com

European Association of Urology

Platinum Priority – Brief Correspondence
Editorial by XXX on pp. x–y of this issue

Initial Experience of ^{68}Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy

Lars Budäus[a,†,*], *Sami-Ramzi Leyh-Bannurah*[a,b,†], *Georg Salomon*[a], *Uwe Michl*[a], *Hans Heinzer*[a], *Hartwig Huland*[a], *Markus Graefen*[a], *Thomas Steuber*[a], *Clemens Rosenbaum*[a,b]

[a] *Martini-Clinic Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Hamburg, Germany;*
[b] *Department of Urology, University Hospital Hamburg-Eppendorf, Hamburg, Germany*

Article info

Article history:
Accepted June 9, 2015

Associate Editor:
Giacomo Novara

Keywords:
Prostate-specific membrane antigen
Positron-emission tomography
Prostate cancer
Lymph node metastasis
Imaging

Abstract

Prostate-specific membrane antigen (PSMA) overexpression theoretically enables targeting of prostate cancer (PCa) metastases using gallium Ga 68 (^{68}Ga)–labeled PSMA ligands for positron emission tomography/computed tomography (PET/CT) imaging. Promising detection rates have been reported when using this approach for functional imaging of recurrent PCa; however, until now, the diagnostic accuracy of ^{68}Ga-PSMA PET/CT for preoperatively identifying lymph node metastases (LNMs) had not been assessed. We retrospectively compared preoperative ^{68}Ga-PSMA PET/CT lymph node (LN) findings with histologic work-up after radical prostatectomy (RP). Overall, 608 LNs containing 53 LNMs were detected during RP. LNMs were present in 12 of 30 patients (40%). The ^{68}Ga-PSMA PET/CT scans identified 4 patients (33.3%) as LN true positive and 8 patients (66.7%) as false negative. Median size of ^{68}Ga-PSMA-PET/CT–detected versus undetected LNMs was 13.6 versus 4.3 mm ($p < 0.05$). Overall sensitivity, specificity, positive predictive value, and negative predictive value of ^{68}Ga-PSMA PET/CT for LNM detection were 33.3%, 100%, 100%, and 69.2%, respectively. Per-side analyses revealed corresponding values of 27.3%, 100%, 100%, and 52.9%. Conversely, ^{68}Ga-PSMA PET/CT enabled tumor visualization in the prostate. In 92.9% of patients, the intraprostatic tumor foci were correctly predicted. Overall, ^{68}Ga-PSMA PET/CT is a promising tool for functional imaging; however, our initial experience revealed substantial influence of LNM size on the diagnostic accuracy of ^{68}Ga-PSMA PET/CT.

Patient summary: We assessed the diagnostic accuracy of ^{68}Ga-PSMA PET/CT in high-risk prostate cancer patients prior to radical prostatectomy. We found that lymph node metastasis detection rates were substantially influenced by lymph node metastasis size.

† Both authors contributed equally.
* Corresponding author. Martini-Clinic Prostate Cancer Center, University Hospital Hamburg-Eppendorf, Martinistr. 52, 20246 Hamburg, Germany. Tel. +49 40 7410 51300; Fax: +49 40 7410 51323.
E-mail address: budaeus@martini-klinik.de (L. Budäus).

Recent series suggest that prostate cancer (PCa) patients with minimal lymph node (LN) involvement can be cured by extended pelvic lymph node dissection (ePLND) when radical prostatectomy (RP) is performed as initial therapy [1]. In addition, despite sparse data on oncologic outcomes, surgical treatment of recurrent PCa is increasingly discussed. These developments underscore the need for a reliable staging modality. Traditionally, conventional imaging criteria of LN

http://dx.doi.org/10.1016/j.eururo.2015.06.010
0302-2838/

metastases (LNMs) are based on nodal size and irregular shape; however, this approach resulted in low sensitivity for smaller LNMs. To overcome these limitations, computed tomography (CT) and magnetic resonance imaging (MRI) were combined with functional imaging by using choline-based imaging (positron emission tomography [PET]).

Recently, gallium Ga 68 (^{68}Ga)–labeled prostate-specific membrane antigen (PSMA) PET/CT, which uses the affinity of the ^{68}Ga-labeled PSMA ligand to PSMA expressing PCa cells, emerged as a new, promising tracer [2]. Especially in patients suffering biochemical recurrence (BCR) after primary therapy, promising results were reported for ^{68}Ga-PSMA PET/CT compared with F 18 fluoromethylcholine [2]. These results were attributed to PSMA overexpression in higher grade, metastasized, or castration-resistant PCa cells and its transmembrane location [3]. Consequently, a dramatic increase of ^{68}Ga-PSMA PET/CT use for LN staging was seen in Europe.

It is uncertain that these promising results can also be applied to LN staging because the majority of reports on ^{68}Ga-PSMA PET/CT stem from BCR cohorts and/or provide only limited histopathologic confirmation of LNM status. We decided to analyze the ability of ^{68}Ga-PSMA PET/CT to detect LNMs in patients referred for RP to the Martini Clinic, a large tertiary referral center in Germany. Between June 2014 and March 2015, 58 patients with pretreatment ^{68}Ga-PSMA PET/CT were available for analysis. All ^{68}Ga-PSMA PET/CT scans were initiated according to the referring urologist's discretion for staging. To minimize the influence of heterogeneous patient characteristics on the diagnostic performance of ^{68}Ga-PSMA PET/CT, our analyses were restricted to a homogenous cohort of 30 patients (Table 1). All patients harbored a nomogram-calculated risk of LNMs >20% [4]. Based on the supposed oncologic benefit of RP, the cohort also comprised selected patients for whom surgery was performed as part of a multimodal treatment, even when LNMs were detected by imaging. All patients underwent an interdisciplinary institutional tumor board and received an informed consent among patient, urologist, and radio-oncologist. Moreover, written consent for retrospective data analyses was given by all patients. All ^{68}Ga-PSMA PET/CT scans were performed nationwide in five imaging centers performing 200–1500 ^{68}Ga-PSMA PET/CT scans per year. The ePLND included a standardized template of fossa obturatoria and arteria iliaca externa, interna, and communis. RP specimens were processed by dedicated uropathologists, and immunhistochemistry was used for assessment of LN status.

Overall, 608 LNs were resected, with 53 harboring metastases (8.7%) in 12 of 30 patients (40.0%) (Table 2). The mean and median LN yields per patient were 20.3 and 18.5 (interquartile range: 13.5–27.5), respectively. The ^{68}Ga-PSMA PET/CT scans identified 4 of 12 patients (33.3%) as LN positive (true positive). No suspicious extrapelvic LNMs or visceral lesions were detected. In eight patients with histologically confirmed LNMs, ^{68}Ga-PSMA PET/CT was negative (false negative; 66.7%). Comparison of intranodal tumor deposit revealed that median size of ^{68}Ga-PSMA PET/CT–detected versus undetected LNMs was 13.6 mm (range: 4.0–20.0 mm) versus 4.3 mm (range: 1.0–10.8 mm)

Table 1 – Patient characteristics (n = 30) stratified by nodal status

	Total patients (n = 30)	No LN metastases (n = 18)	LN metastases (n = 12)	p
Age, yr, mean, median (range)	62.3, 63.0 (44.0–75.0)	62.1, 62.5 (44.0–74.0)	62.7, 64.0 (47.0–75.0)	0.755
PSA, ng/ml, mean, median (range)	38.9, 8.8 (1.4–376.0)	11.9, 8.0 (4.2–36.6)	79.5, 24.1 (1.4–376.0)	0.021
Gleason score at RP (%)				0.015
3 + 4	9 (30.0)	8 (44.4)	1 (8.3)	
4 + 3	10 (33.3)	7 (38.9)	3 (25.0)	
≥4 + 4	11 (36.7)	3 (16.7)	8 (66.7)	
pT stage at RP, no. (%)				<0.001
pT2	11 (36.7)	11 (61.1)	0 (0.0)	
pT3a	4 (13.3)	4 (22.2)	0 (0.0)	
pT3b	12 (40.0)	3 (16.7)	9 (75.0)	
pT4	3 (10.0)	0 (0.0)	3 (25.0)	
Intraprostatic PCa size, mm, mean, median (range)	33.3, 32.5 (8.0–63.0)	27.6, 28.4 (8.0–39.0)	41.8, 40.5 (28.0–63.0)	0.003
Intraprostatic PCa volume, ml, mean, median (range)	11.7, 5.4 (0.3–68.1)	4.1, 4.3 (0.3–8.0)	23.0, 16.0 (3.4–68.1)	<0.001
LNs removed, no. (%)	608 (100)	393 (64.6)	215 (35.4)	0.346
LNMs removed, no. (%)	53 (100)	–	53 (100)	
Intranodal LNM size, mm *, mean, median (range)	7.3, 4.7 (1.0–20.0)	–	7.3, 4.7 (1.0–20.0)	
Overall LNM size, mm *, mean, median (range)	23.5, 23.0 (4.0–64.0)	–	23.5, 23.0 (4.0–64.0)	
PSMA, MBq, mean, median (range)	169.4, 165.0 (106.0–269.0)	150.5, 158.5 (106.0–170.0)	207.3, 200.0 (153.0–269.0)	0.167
SUV, maximal LN, mean, median (range)	5.3, 5.3 (5.1–5.5)	–	5.3, 5.3 (5.1–5.5)	
SUV, maximum PCa, mean, median (range)	8.3, 6.2 (1.3–22.3)	8.1, 5.6 (2.1–20.5)	8.6, 6.9 (1.3–22.3)	0.849

LN = lymph node; LNM = lymph node metastasis; PCa = prostate cancer; PSA = prostate specific antigene; PSMA = prostate-specific membrane antigen; RP = radical prostatectomy; SUV = standardized uptake value
* Largest/index lymph node per patient is presented.

Please cite this article in press as: Budäus L, et al. Initial Experience of ^{68}Ga-PSMA PET/CT Imaging in High-risk Prostate Cancer Patients Prior to Radical Prostatectomy. Eur Urol (2015), http://dx.doi.org/10.1016/j.eururo.2015.06.010